Nextleaf Solutions Enters into Patent Licensing Agreement
Royalty anticipated to deliver over $3.0MM to the Company in 2020(i)
VANCOUVER, Dec. 17, 2019 /CNW/ - Nextleaf Solutions Ltd. ("Nextleaf", "OILS", or the "Company") (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA), a Coquitlam-based company developing intellectual property for the extraction and purification of cannabinoids, is pleased to announce that it has entered into a strategic agreement (the "Agreement") with a British Columbia-based cannabis processing equipment distribution company (the "Licensee").
The Agreement permits the Licensee, on a non-exclusive basis, to commercialize and distribute certain intellectual property, specifically, three issued and pending patents related to post-extraction processing equipment ("IP") developed by Nextleaf. OILS will provide the Licensee with initial working capital and strategic support during the indefinite term of the Agreement. OILS may terminate the Agreement if the Licensee does not meet certain minimum annual sales targets.
OILS will receive a royalty equal to 20% of the Licensee's gross revenue from all sources (the "Royalty") in exchange for, among other consideration, the licensed IP. Based on the Licensee's current product backlog and 2020 projections, OILS estimates the Royalty could yield over $3,000,000 in royalty fees to Nextleaf in the 2020 calendar year, with initial revenue expected to commence in the immediate term.(i)
"We believe this is an ideal partnership with a company whose management has a proven track record of building one of the industry's largest cannabis processing equipment distributors," stated Charles Ackerman, Chief Financial Officer of Nextleaf. "This deal allows OILS to continue its work to efficiently monetize its patent portfolio globally. It also brings closer to its previously announced goal of $5,000,000-$10,000,000 in gross revenue from IP licensing alone in the next 12 months.(ii) We believe IP licensing has the potential to represent up to 10-20% of our gross annual revenue" continued Ackerman.(i)
In addition to the development and monetization of its IP portfolio, OILS continues to focus on assisting Nextleaf Labs Ltd., a Health Canada licensed standard processor, to reach full commercial production including the production and sale of bulk CBD and THC oils. Nextleaf expects to be in a position to announce additional commercial agreements during the first calendar quarter of 2020.
About Nextleaf Solutions
Nextleaf Solutions Ltd. ("OILS") is developing disruptive intellectual property for the extraction and distillation of cannabinoids. OILS owns a portfolio of 10 issued patents pertaining to industrial-scale production of distilled CBD and THC oils, the key ingredients used in the manufacturing of standardized cannabinoid based products. OILS commercializes its IP portfolio through IP licensing, B2B processing, and supplying THC and CBD oils to qualified Canadian and international partners through Nextleaf Labs Ltd., a Health Canada licensed standard processor.
Nextleaf Solutions trades as OILS on the Canadian Securities Exchange, OILFF on the OTCQB Market in the United States, and L0MA on the Frankfurt Stock Exchange.
Follow OILS across social media platforms: Twitter, LinkedIn, Facebook, and Instagram.
On behalf of the Board of Directors of the Company,
Paul Pedersen, CEO
Certain statements contained in this press release constitute "forward-looking statements". All statements other than statements of historical fact contained in this press release, including, without limitation, those regarding the Licensee's current backlog and projections for the 2020 calendar year, the Royalty expected to be received by the Company during the 2020 calendar year, the Company's ability to capitalize on its IP portfolio and in jurisdictions outside of Canada, the Company's expected gross revenue from IP licensing during the 2020 calendar year, the percentage of the Company's revenue expected to be received from IP licensing, the Company's expectations regarding the entering into of new commercial agreements in the first quarter of 2020, and the Company's strategy, plans, objectives, goals and targets, and any statements preceded by, followed by or that include the words "believe", "expect", "aim", "intend", "plan", "continue", "will", "may", "would", "anticipate", "estimate", "forecast", "predict", "project", "seek", "should" or similar expressions or the negative thereof, are forward-looking statements. These statements are not historical facts but instead represent only the Company's expectations, estimates and projections regarding future events. These statements are not guarantees of future performance and involve assumptions, risks and uncertainties that are difficult to predict. Therefore, actual results may differ materially from what is expressed, implied or forecasted in such forward-looking statements. Additional factors that could cause actual results, performance or achievements to differ materially include, but are not limited to the risk factors discussed in the Company's MD&A for the most recent fiscal period. Management provides forward-looking statements because it believes they provide useful information to investors when considering their investment objectives and cautions investors not to place undue reliance on forward-looking information. Consequently, all of the forward-looking statements made in this press release are qualified by these cautionary statements and other cautionary statements or factors contained herein, and there can be no assurance that the actual results or developments will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, the Company. These forward-looking statements are made as of the date of this press release and the Company assumes no obligation to update or revise them to reflect subsequent information, events or circumstances or otherwise, except as required by law. The CSE has not reviewed, approved or disapproved the contents of this press release.